m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00008)
| Regulator Name | YTH domain-containing family protein 2 (YTHDF2) | ||||
|---|---|---|---|---|---|
| Synonyms |
DF2; CLL-associated antigen KW-14; High-glucose-regulated protein 8; Renal carcinoma antigen NY-REN-2; HGRG8
Click to Show/Hide
|
||||
| Gene Name | YTHDF2 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Apoptosis regulator Bcl-2 (BCL-2)
MCI-186 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [2] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [3] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [4] | ||
Oblimersen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [5] | ||
RG7601 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [6] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [7] | ||
APG-1252 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [8] | ||
APG-2575 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [9] | ||
AZD0466 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [10] | ||
Beclanorsen [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [11] | ||
Gossypol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [12] | ||
Obatoclax [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [13] | ||
PNT-2258 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [14] | ||
AI-850 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [15] | ||
BCL201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [16] | ||
BGB-11417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [17] | ||
BP1002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [18] | ||
LP-108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [19] | ||
Pc4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [20] | ||
VOB560 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [21] | ||
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [22] | ||
4,5-dibenzylbenzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [23] | ||
5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
Apogossypol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [25] | ||
BP-100-1.02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [26] | ||
modified HA14-1 compounds (cancer) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
QEDIIRNIARHLAQVGDSMDR [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
TW-37 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [27] | ||
WL-276 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [28] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [29] | ||
C-X-C chemokine receptor type 4 (CXCR4)
Plerixafor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Plerixafor. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Plerixafor through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [31] | ||
AMD-070 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for AMD-070. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AMD-070 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [32] | ||
Balixafortide [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Balixafortide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Balixafortide through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [4], [30] | ||
BL-8040 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for BL-8040. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BL-8040 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [33] | ||
Ulocuplumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Ulocuplumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ulocuplumab through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [34] | ||
CTCE-9908 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-9908. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CTCE-9908 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [15], [30] | ||
POL-6326 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for POL-6326. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of POL-6326 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [35] | ||
TG-0054 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for TG-0054. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TG-0054 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [36] | ||
USL311 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for USL311. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of USL311 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [37] | ||
ALX-0651 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ALX-0651. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ALX-0651 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [38] | ||
BMS-936564 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for BMS-936564. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-936564 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [33] | ||
CTCE-0214 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-0214. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CTCE-0214 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [39] | ||
GMI-1359 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for GMI-1359. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GMI-1359 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [40] | ||
LY2624587 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for LY2624587. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY2624587 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [41] | ||
MSX-122 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MSX-122. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MSX-122 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [42] | ||
PF-06747143 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for PF-06747143. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-06747143 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [43] | ||
MAb173 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MAb173. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MAb173 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [44] | ||
AT-009 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for AT-009. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AT-009 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
ATI-2341 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ATI-2341. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ATI-2341 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
CTCE-0324 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CTCE-0324. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CTCE-0324 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [46] | ||
CX-02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CX-02. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CX-02 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
CXCL8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CXCL8. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CXCL8 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [47] | ||
CXCR4 gene disrupted T cells [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for CXCR4 gene disrupted T cells. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CXCR4 gene disrupted T cells through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [49] | ||
Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [50] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
GSK-812397 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for GSK-812397. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK-812397 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
isothiourea-1a [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for isothiourea-1a. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of isothiourea-1a through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [46] | ||
isothiourea-1t [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for isothiourea-1t. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of isothiourea-1t through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [51] | ||
KUR-CXCR4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for KUR-CXCR4. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KUR-CXCR4 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
LP-0067 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for LP-0067. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LP-0067 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
NB-325 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for NB-325. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NB-325 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
ND-401 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for ND-401. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ND-401 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [45] | ||
T134 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T134. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of T134 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [51] | ||
T140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T140. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of T140 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [51] | ||
T22 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for T22. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of T22 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [52] | ||
TN-14003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for TN-14003. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TN-14003 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [48] | ||
viral macrophage inflammatory protein-II [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for viral macrophage inflammatory protein-II. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of viral macrophage inflammatory protein-II through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [53] | ||
Garnocestim [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for Garnocestim. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Garnocestim through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [54] | ||
KRH-2731 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for KRH-2731. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KRH-2731 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [55] | ||
SURADISTA [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for SURADISTA. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SURADISTA through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). | [30], [56] | ||
CREB-binding protein (CREBBP)
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for C 82. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of C 82 through regulating the expression of CREB-binding protein (CREBBP). | [57], [58] | ||
CCS1477 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for CCS1477. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CCS1477 through regulating the expression of CREB-binding protein (CREBBP). | [57], [59] | ||
PRI-724 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for PRI-724. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PRI-724 through regulating the expression of CREB-binding protein (CREBBP). | [57], [60] | ||
FT-7051 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for FT-7051. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FT-7051 through regulating the expression of CREB-binding protein (CREBBP). | [57], [61] | ||
I-CBP112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for I-CBP112. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of I-CBP112 through regulating the expression of CREB-binding protein (CREBBP). | [57], [62] | ||
ischemin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for ischemin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ischemin through regulating the expression of CREB-binding protein (CREBBP). | [57], [63] | ||
SGC-CBP30 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for SGC-CBP30. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SGC-CBP30 through regulating the expression of CREB-binding protein (CREBBP). | [57], [64] | ||
Cyclin A2 (CCNA2)
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide through regulating the expression of Cyclin A2 (CCNA2). | [65], [66] | ||
4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine through regulating the expression of Cyclin A2 (CCNA2). | [65], [67] | ||
6-(3-Amino-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin A2 (CCNA2). | [65], [68] | ||
6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin A2 (CCNA2). | [65], [69] | ||
6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine through regulating the expression of Cyclin A2 (CCNA2). | [65], [69] | ||
6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine through regulating the expression of Cyclin A2 (CCNA2). | [65], [70] | ||
6-O-Cyclohexylmethyl Guanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for 6-O-Cyclohexylmethyl Guanine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-O-Cyclohexylmethyl Guanine through regulating the expression of Cyclin A2 (CCNA2). | [65], [69] | ||
aloisine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for aloisine A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of aloisine A through regulating the expression of Cyclin A2 (CCNA2). | [65], [71] | ||
GW-8510 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for GW-8510. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-8510 through regulating the expression of Cyclin A2 (CCNA2). | [65], [72] | ||
MERIOLIN 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 1 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 2 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 3. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 3 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 4. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 4 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 5. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 5 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 6. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 6 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
MERIOLIN 7 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 7. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 7 through regulating the expression of Cyclin A2 (CCNA2). | [65], [74] | ||
MERIOLIN 8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for MERIOLIN 8. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 8 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
NU-6027 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for NU-6027. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU-6027 through regulating the expression of Cyclin A2 (CCNA2). | [65], [73] | ||
Purvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for Purvalanol A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Purvalanol A through regulating the expression of Cyclin A2 (CCNA2). | [65], [75] | ||
RESCOVITINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin A2 (CCNA2). | [65], [76] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin A2 (CCNA2) is a therapeutic target for PD-0183812. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin A2 (CCNA2). | [65], [77] | ||
Cyclin-dependent kinase 2 (CDK2)
PHA848125 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA848125. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PHA848125 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
Ro 31-7453 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Ro 31-7453. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [79] | ||
Roscovitine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Roscovitine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Roscovitine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [80] | ||
TG02 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for TG02. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TG02 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [81] | ||
AG-024322 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AG-024322. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [82] | ||
AT7519 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AT7519. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AT7519 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [83] | ||
AZD-5438 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AZD-5438. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD-5438 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [84] | ||
CYC065 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for CYC065. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CYC065 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [85] | ||
FN-1501 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for FN-1501. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FN-1501 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [86] | ||
PF-07104091 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PF-07104091. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-07104091 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [87] | ||
PHA-793887 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA-793887. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [88] | ||
RGB-286638 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RGB-286638. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [81] | ||
SNS-032 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SNS-032. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SNS-032 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [15], [65] | ||
INOC-005 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for INOC-005. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of INOC-005 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
L-751250 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for L-751250. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of L-751250 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [81] | ||
1-Amino-6-Cyclohex-3-Enylmethyloxypurine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 1-Amino-6-Cyclohex-3-Enylmethyloxypurine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 1-Amino-6-Cyclohex-3-Enylmethyloxypurine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
10Z-Hymenialdisine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 10Z-Hymenialdisine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 10Z-Hymenialdisine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
2-Amino-6-Chloropyrazine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 2-Amino-6-Chloropyrazine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-Amino-6-Chloropyrazine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [91] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [92] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [93] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [91] | ||
4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
5-hydroxynaphthalene-1-sulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 5-hydroxynaphthalene-1-sulfonamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5-hydroxynaphthalene-1-sulfonamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
6-(3-Amino-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [68] | ||
6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [69] | ||
6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [69] | ||
6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [69] | ||
6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
6-O-Cyclohexylmethyl Guanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-O-Cyclohexylmethyl Guanine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-O-Cyclohexylmethyl Guanine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
9-Nitropaullone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 9-Nitropaullone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 9-Nitropaullone through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
aloisine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aloisine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of aloisine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [70] | ||
aloisine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aloisine A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of aloisine A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [94] | ||
aminopurvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aminopurvalanol A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of aminopurvalanol A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [95] | ||
Benzyl-(9-isopropyl-9H-purin-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Benzyl-(9-isopropyl-9H-purin-6-yl)-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Benzyl-(9-isopropyl-9H-purin-6-yl)-amine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS 536924 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [72] | ||
BMS-265246 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS-265246. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-265246 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [96] | ||
BOHEMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BOHEMINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BOHEMINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
BX-795 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BX-795. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BX-795 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [96] | ||
BX-912 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BX-912. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BX-912 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [97] | ||
Cdk4 inhibitor III [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Cdk4 inhibitor III. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cdk4 inhibitor III through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [98] | ||
CVT-313 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for CVT-313. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CVT-313 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [99] | ||
Double Oxidized Cysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Double Oxidized Cysteine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [98] | ||
GW-8510 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for GW-8510. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-8510 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [72] | ||
Indirubin-3'-monoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Indirubin-3'-monoxime. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Indirubin-3'-monoxime through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
Indirubin-5-sulfonate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Indirubin-5-sulfonate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Indirubin-5-sulfonate through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
JNJ 7706621 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for JNJ 7706621. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of JNJ 7706621 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [91] | ||
K00024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for K00024. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [100] | ||
Lysine Nz-Carboxylic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Lysine Nz-Carboxylic Acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Lysine Nz-Carboxylic Acid through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
MERIOLIN 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 1 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [91] | ||
MERIOLIN 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
MERIOLIN 3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 3. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 3 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
MERIOLIN 4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 4. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 4 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
MERIOLIN 5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 5. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 5 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
MERIOLIN 6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 6. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 6 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
MERIOLIN 8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 8. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MERIOLIN 8 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [89] | ||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [101] | ||
N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [102] | ||
N-phenyl-1H-pyrazole-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-phenyl-1H-pyrazole-3-carboxamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-phenyl-1H-pyrazole-3-carboxamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
NSC-625987 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NSC-625987. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NSC-625987 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [103] | ||
NU-6027 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU-6027. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU-6027 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [73] | ||
NU-6102 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU-6102. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU-6102 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [74] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU6140. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [104] | ||
Oxindole 95 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Oxindole 95. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Oxindole 95 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [78] | ||
PF-228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PF-228. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-228 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [75] | ||
PHA-690509 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA-690509. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PHA-690509 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [105] | ||
PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
Purvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Purvalanol A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Purvalanol A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [106] | ||
PYRAZOLOPYRIDAZINE 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [107] | ||
PYRAZOLOPYRIDAZINE 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [108] | ||
RESCOVITINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [92] | ||
SCH-546909 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SCH-546909. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SCH-546909 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [109] | ||
SU9516 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SU9516. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SU9516 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [107] | ||
TRIAZOLOPYRIMIDINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for TRIAZOLOPYRIMIDINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TRIAZOLOPYRIMIDINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [90] | ||
VER-54505 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for VER-54505. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VER-54505 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [105] | ||
BAY 10-00394 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BAY 10-00394. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [110] | ||
Olomoucine [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Olomoucine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Olomoucine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [111] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PD-0183812. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [112] | ||
R547 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for R547. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [81] | ||
SCH 727965 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SCH 727965. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SCH 727965 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [113] | ||
ZK 304709 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for ZK 304709. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [65], [81] | ||
DNA-binding factor KBF1 (p105)
CAT 1004 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). | [114], [115] | ||
P54 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for P54. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of P54 through regulating the expression of DNA-binding factor KBF1 (p105). | [114], [116] | ||
Endoplasmic reticulum chaperone BiP (HSPA5)
IT-139 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for IT-139. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IT-139 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [117], [118] | ||
NKP-1339 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for NKP-1339. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NKP-1339 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [117], [119] | ||
SAM-6 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for SAM-6. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SAM-6 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [117], [120] | ||
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [80], [121] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [122] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [123] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [124] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [125] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [126] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [127] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [128] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [129] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [130] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [128] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [131] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [133] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [134] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [135] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [136] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [137] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [138] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [139] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [140] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [141] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [142] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [121] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [123] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [122] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [143] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [144] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [145] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [146] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [80], [121] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [141] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [147] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [148] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [121] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [121] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [121] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [121] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [33], [121] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [149] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [150] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [151] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [152] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [153] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [154] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [155] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [156] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [157] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [158] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [33], [121] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [159] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [160] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [140] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [161] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [162] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [163] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [164] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [140] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [165] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [166] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [167] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [168] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [169] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [170] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [171] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [172] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [173] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [174] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [15], [121] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [175] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [33], [121] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [176] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [177] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [33], [121] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [178] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [180] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [181] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [182] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [183] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [91], [121] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [184] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [185] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [186] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [187] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [188] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [189] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [190] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [180] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [191] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [192] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [194] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [195] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [196] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [94], [121] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [186] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [186] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [197] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [179] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [198] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [199] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [190] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [191] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [200] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [192] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [201] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [202] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [203] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [204] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [186] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [205] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [91], [121] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [206] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [193] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [207] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [208] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [209] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [210] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [198] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [206] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [182] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [180] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [208] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [91], [121] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [180] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [211] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [181] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [181] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [180] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [210] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [157] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [212] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [213] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [205] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [91], [121] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [214] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [94], [121] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [132] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [215] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [80], [121] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [216] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [157] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [217] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [218] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [219] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [220] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [121], [221] | ||
Fyn tyrosine protein kinase (FYN)
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for JNJ-26483327. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of JNJ-26483327 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [80], [222] | ||
1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane through regulating the expression of Fyn tyrosine protein kinase (FYN). | [222], [223] | ||
CEP-5104 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for CEP-5104. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CEP-5104 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [173], [222] | ||
CEP-6331 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for CEP-6331. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CEP-6331 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [222], [224] | ||
JNJ-10198409 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for JNJ-10198409. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of JNJ-10198409 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [187], [222] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro-4396686 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [222], [224] | ||
G1/S-specific cyclin-D1 (CCND1)
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [225], [226] | ||
Briciclib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [15], [225] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [91], [225] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [91], [225] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [225], [227] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [91], [225] | ||
7-hydroxycoumarin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [74], [225] | ||
Heat shock protein 90 alpha (HSP90A)
Amlexanox [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Amlexanox. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Amlexanox through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
Cromoglicate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Cromoglicate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Cromoglicate through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
BIIB-021 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for BIIB-021. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BIIB-021 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [229] | ||
Efungumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Efungumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Efungumab through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
KW-2478 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KW-2478. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KW-2478 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [231] | ||
NVP-AUY922 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for NVP-AUY922. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NVP-AUY922 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [232] | ||
SNX-5422 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for SNX-5422. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SNX-5422 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
Tanespimycin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Tanespimycin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Tanespimycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [233] | ||
VER 50589 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for VER 50589. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VER 50589 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [234] | ||
Alvespimycin hydrochloride [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Alvespimycin hydrochloride. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Alvespimycin hydrochloride through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [235] | ||
AT13387 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for AT13387. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AT13387 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
BIIB 028 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for BIIB 028. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BIIB 028 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [236] | ||
Debio 0932 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Debio 0932. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Debio 0932 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [237] | ||
PU-AD [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU-AD. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PU-AD through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [231] | ||
PU3 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU3. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PU3 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [238] | ||
RTA-901 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for RTA-901. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RTA-901 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [239] | ||
CCT-018159 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for CCT-018159. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CCT-018159 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [240] | ||
KOS-2484 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KOS-2484. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KOS-2484 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
17-desmethoxy-17-aminogeldanamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 17-desmethoxy-17-aminogeldanamycin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 17-desmethoxy-17-aminogeldanamycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [241] | ||
2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
2-Methyl-2,4-Pentanediol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 2-Methyl-2,4-Pentanediol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-Methyl-2,4-Pentanediol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [90], [228] | ||
Geldanamycin-estradiol hybrid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Geldanamycin-estradiol hybrid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Geldanamycin-estradiol hybrid through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [242] | ||
GNF-PF-67 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for GNF-PF-67. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GNF-PF-67 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [241] | ||
KOSN1559 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KOSN1559. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KOSN1559 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [230] | ||
Macbecin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Macbecin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Macbecin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [243] | ||
PU24S [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU24S. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PU24S through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [89], [228] | ||
Radicicol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Radicicol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Radicicol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [244] | ||
RHEIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for RHEIN. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RHEIN through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [245] | ||
SNX-2112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for SNX-2112. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SNX-2112 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [242] | ||
VER-49009 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for VER-49009. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VER-49009 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [246] | ||
ZEARALANONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for ZEARALANONE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZEARALANONE through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [241] | ||
EC-154 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for EC-154. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EC-154 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [247] | ||
Geldanamycin [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Geldanamycin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Geldanamycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [248] | ||
HBP-347 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for HBP-347. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HBP-347 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [249] | ||
IPI-493 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for IPI-493. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IPI-493 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [228], [250] | ||
Heat shock protein beta-1 (HSPB1)
AZX-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein beta-1 (HSPB1) is a therapeutic target for AZX-100. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZX-100 through regulating the expression of Heat shock protein beta-1 (HSPB1). | [228], [251] | ||
SB-242235 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein beta-1 (HSPB1) is a therapeutic target for SB-242235. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SB-242235 through regulating the expression of Heat shock protein beta-1 (HSPB1). | [228], [252] | ||
Histone-lysine N-methyltransferase SETD7 (SETD7)
(R)-PFI-2 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone-lysine N-methyltransferase SETD7 (SETD7) is a therapeutic target for (R)-PFI-2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (R)-PFI-2 through regulating the expression of Histone-lysine N-methyltransferase SETD7 (SETD7). | [253], [254] | ||
Insulin receptor substrate-1 (IRS1)
NT219 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin receptor substrate-1 (IRS1) is a therapeutic target for NT219. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NT219 through regulating the expression of Insulin receptor substrate-1 (IRS1). | [255], [256] | ||
Integrin beta-1 (ITGB1)
131I-radretumab [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for 131I-radretumab. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 131I-radretumab through regulating the expression of Integrin beta-1 (ITGB1). | [257], [258] | ||
JSM 6427 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for JSM 6427. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of JSM 6427 through regulating the expression of Integrin beta-1 (ITGB1). | [257], [259] | ||
OS2966 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for OS2966. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OS2966 through regulating the expression of Integrin beta-1 (ITGB1). | [257], [260] | ||
C(-GRGDfL-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for C(-GRGDfL-). The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of C(-GRGDfL-) through regulating the expression of Integrin beta-1 (ITGB1). | [257], [261] | ||
MK-0668 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for MK-0668. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MK-0668 through regulating the expression of Integrin beta-1 (ITGB1). | [257], [262] | ||
SB-265123 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for SB-265123. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SB-265123 through regulating the expression of Integrin beta-1 (ITGB1). | [257], [263] | ||
Interferon regulatory factor 3 (IRF3)
Piceatannol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon regulatory factor 3 (IRF3) is a therapeutic target for Piceatannol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Piceatannol through regulating the expression of Interferon regulatory factor 3 (IRF3). | [264], [265] | ||
Interferon-beta (IFNB1)
Interferon beta-1a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta-1a. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Interferon beta-1a through regulating the expression of Interferon-beta (IFNB1). | [266], [267] | ||
PEGylated IFN beta 1-a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PEGylated IFN beta 1-a. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PEGylated IFN beta 1-a through regulating the expression of Interferon-beta (IFNB1). | [266], [268] | ||
PLEGRIDY [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PLEGRIDY. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PLEGRIDY through regulating the expression of Interferon-beta (IFNB1). | [266], [269] | ||
Biferonex [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Biferonex. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Biferonex through regulating the expression of Interferon-beta (IFNB1). | [266], [270] | ||
FP-1201 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). | [266], [271] | ||
NU-100 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for NU-100. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU-100 through regulating the expression of Interferon-beta (IFNB1). | [266], [272] | ||
AZ-01, PEGylated interferon-beta [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for AZ-01, PEGylated interferon-beta. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZ-01, PEGylated interferon-beta through regulating the expression of Interferon-beta (IFNB1). | [140], [266] | ||
Interferon beta 1a [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta 1a. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Interferon beta 1a through regulating the expression of Interferon-beta (IFNB1). | [266], [273] | ||
PF-06823859 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PF-06823859. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-06823859 through regulating the expression of Interferon-beta (IFNB1). | [266], [273] | ||
ARX-424 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for ARX-424. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ARX-424 through regulating the expression of Interferon-beta (IFNB1). | [266], [274] | ||
Gene therapy, IFN-b [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Gene therapy, IFN-b. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Gene therapy, IFN-b through regulating the expression of Interferon-beta (IFNB1). | [31], [266] | ||
TV-1390 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for TV-1390. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TV-1390 through regulating the expression of Interferon-beta (IFNB1). | [266], [273] | ||
Maxy-10 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Maxy-10. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Maxy-10 through regulating the expression of Interferon-beta (IFNB1). | [266], [275] | ||
Interleukin-11 (IL11)
VM-501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-11 (IL11) is a therapeutic target for VM-501. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VM-501 through regulating the expression of Interleukin-11 (IL11). | [276], [277] | ||
Kruppel like factor 4 (KLF4)
APTO-253 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Kruppel like factor 4 (KLF4) is a therapeutic target for APTO-253. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of APTO-253 through regulating the expression of Kruppel like factor 4 (KLF4). | [253], [278] | ||
Mitochondrial matrix protein P1 (HSPD1)
DiaPep-277 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mitochondrial matrix protein P1 (HSPD1) is a therapeutic target for DiaPep-277. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DiaPep-277 through regulating the expression of Mitochondrial matrix protein P1 (HSPD1). | [228], [279] | ||
Mothers against decapentaplegic homolog 3 (SMAD3)
FLUORESCEIN [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [280], [281] | ||
SIS-3 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for SIS-3. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SIS-3 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [241], [280] | ||
ELLAGIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [241], [280] | ||
GNF-PF-2272 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for GNF-PF-2272. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GNF-PF-2272 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [280], [282] | ||
Mothers against decapentaplegic homolog 7 (SMAD7)
GED-0301 [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [284] | ||
| Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [285] | |||
ISIS 28465 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28465. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 28465 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [286] | ||
ISIS 28466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28466. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 28466 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [286] | ||
ISIS 28472 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28472. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 28472 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [286] | ||
ISIS 28477 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28477. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 28477 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [283], [287] | ||
Multidrug resistance-associated protein 7 (ABCC10)
Docetaxel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Multidrug resistance-associated protein 7 (ABCC10) is a therapeutic target for Docetaxel. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Docetaxel through regulating the expression of Multidrug resistance-associated protein 7 (ABCC10). | [288], [289] | ||
Tenofovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Multidrug resistance-associated protein 7 (ABCC10) is a therapeutic target for Tenofovir. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Tenofovir through regulating the expression of Multidrug resistance-associated protein 7 (ABCC10). | [288], [290] | ||
Myosin-7 (MYH7)
UshStat [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Myosin-7 (MYH7) is a therapeutic target for UshStat. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of UshStat through regulating the expression of Myosin-7 (MYH7). | [291], [292] | ||
Notch-1 receptor (NOTCH1)
LY3039478 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for LY3039478. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY3039478 through regulating the expression of Notch-1 receptor (NOTCH1). | [293], [294] | ||
OMP-52M51 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). | [15], [293] | ||
Nucleobindin-1 (NUCB1)
KML110 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nucleobindin-1 (NUCB1) is a therapeutic target for KML110. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KML110 through regulating the expression of Nucleobindin-1 (NUCB1). | [295], [296] | ||
MJN228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nucleobindin-1 (NUCB1) is a therapeutic target for MJN228. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MJN228 through regulating the expression of Nucleobindin-1 (NUCB1). | [295], [297] | ||
Oxysterols receptor LXR-alpha (NR1H3)
12,17-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 12,17-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 12,17-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
12-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 12-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 12-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
17-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 17-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 17-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
2-(2-hexylphenyl)isoindoline-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 2-(2-hexylphenyl)isoindoline-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(2-hexylphenyl)isoindoline-1,3-dione through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [300] | ||
2-(2-phenethylphenyl)isoindoline-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 2-(2-phenethylphenyl)isoindoline-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(2-phenethylphenyl)isoindoline-1,3-dione through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [301] | ||
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [302] | ||
22R-hydroxycholesterol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 22R-hydroxycholesterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 22R-hydroxycholesterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [303] | ||
24(S), 25-epoxycholesterol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 24(S), 25-epoxycholesterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 24(S), 25-epoxycholesterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [304] | ||
24(S)-hydroxycholesterol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 24(S)-hydroxycholesterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 24(S)-hydroxycholesterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [305] | ||
27-hydroxycholesterol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 27-hydroxycholesterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 27-hydroxycholesterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [302] | ||
4,12,17-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 4,12,17-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4,12,17-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
4,17-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 4,17-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4,17-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
4-dehydroxyriccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 4-dehydroxyriccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-dehydroxyriccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [299] | ||
acetyl-podocarpic dimer [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for acetyl-podocarpic dimer. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of acetyl-podocarpic dimer through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [306] | ||
AZ12260493 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for AZ12260493. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZ12260493 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [307] | ||
desmosterol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for desmosterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of desmosterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [308] | ||
GSK-9772 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for GSK-9772. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK-9772 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [309] | ||
GSK2033 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for GSK2033. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK2033 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [310] | ||
Guttiferone I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for Guttiferone I. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Guttiferone I through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [311] | ||
GW-3965 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for GW-3965. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-3965 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [312] | ||
L-783483 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for L-783483. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of L-783483 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [313] | ||
N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [314] | ||
N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [300] | ||
N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [300] | ||
N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [300] | ||
paxilline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for paxilline. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of paxilline through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [315] | ||
Riccardin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for Riccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Riccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [309] | ||
SR9238 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for SR9238. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SR9238 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [316] | ||
WAY-214950 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for WAY-214950. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WAY-214950 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [309] | ||
WAY-254011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for WAY-254011. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WAY-254011 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). | [298], [300] | ||
Peroxisome proliferator-activated receptor alpha (PPARA)
Bezafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Bezafibrate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Bezafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [318] | ||
Ciprofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ciprofibrate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ciprofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [319] | ||
Fenofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fenofibrate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [320] | ||
Lobeglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Lobeglitazone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Lobeglitazone through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [321] | ||
Pemafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Pemafibrate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pemafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [318] | ||
BMS-298585 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-298585. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-298585 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [322] | ||
CS-038 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [323] | ||
GFT-505 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT-505. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GFT-505 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [324] | ||
Imiglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Imiglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Imiglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [325] | ||
Ragaglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ragaglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ragaglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [326] | ||
TESAGLITAZAR [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TESAGLITAZAR. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TESAGLITAZAR through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [327] | ||
ZYH-1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH-1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZYH-1 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [328] | ||
GFT14 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT14. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GFT14 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [329] | ||
LY-518674 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-518674. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY-518674 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [330] | ||
Naveglitazar [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Naveglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Naveglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [140], [317] | ||
ONO-5129 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ONO-5129. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ONO-5129 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [331] | ||
ZYH7 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH7. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZYH7 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [332] | ||
AVE0897 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE0897. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AVE0897 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [333] | ||
CDT-fenofibrate [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CDT-fenofibrate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CDT-fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [334] | ||
GW-409544 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-409544. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-409544 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [335] | ||
Oxeglitazar [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Oxeglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Oxeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [336] | ||
TPST-1120 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TPST-1120. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TPST-1120 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [337] | ||
MC-3001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3001. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MC-3001 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [338] | ||
MC-3002 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3002. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MC-3002 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [339] | ||
PIRINIXIC ACID [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for PIRINIXIC ACID. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PIRINIXIC ACID through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [340] | ||
Romazarit [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Romazarit. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Romazarit through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [140], [317] | ||
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [341] | ||
(E)-12-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-12-Nitrooctadec-12-enoic Acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (E)-12-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [342] | ||
(E)-13-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-13-Nitrooctadec-12-enoic Acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (E)-13-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [342] | ||
(E)-4-(3,5-dimethoxystyryl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-4-(3,5-dimethoxystyryl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (E)-4-(3,5-dimethoxystyryl)phenol through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [343] | ||
8S-HETE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for 8S-HETE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 8S-HETE through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [328] | ||
AD-5061 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AD-5061. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AD-5061 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [344] | ||
BMS-687453 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-687453. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-687453 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [345] | ||
CP-775146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CP-775146. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CP-775146 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [89], [317] | ||
DB-900 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DB-900. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DB-900 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [346] | ||
Deoxy-Bigchap [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Deoxy-Bigchap. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Deoxy-Bigchap through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [347] | ||
DRF 2519 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 2519. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DRF 2519 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [348] | ||
eicosatetranoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for eicosatetranoic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of eicosatetranoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [349] | ||
Fibrates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fibrates. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Fibrates through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [350] | ||
GSK-9578 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-9578. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK-9578 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [342] | ||
GW-2331 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [351] | ||
GW7647 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW7647. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW7647 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [352] | ||
L-165461 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-165461. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of L-165461 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [350] | ||
L-796449 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-796449. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of L-796449 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [318] | ||
LL-6531 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LL-6531. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LL-6531 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [353] | ||
LY-465608 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-465608. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY-465608 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [354] | ||
N-oleoylethanolamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for N-oleoylethanolamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-oleoylethanolamide through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [355] | ||
pristanic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for pristanic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of pristanic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [356] | ||
reglitazar [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for reglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of reglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [357] | ||
TZD18 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TZD18. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TZD18 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [358] | ||
ZY H2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZY H2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ZY H2 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [359] | ||
Aleglitazar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Aleglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Aleglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [360] | ||
AR-H049020 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AR-H049020. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AR-H049020 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [356] | ||
AVE-0847 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-0847. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AVE-0847 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [361] | ||
AVE-8134 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-8134. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AVE-8134 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [362] | ||
BM-17.0744 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BM-17.0744. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BM-17.0744 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [140], [317] | ||
BVT-142 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BVT-142. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BVT-142 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [363] | ||
CS-204 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-204. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CS-204 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [364] | ||
CS-207 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-207. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CS-207 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [365] | ||
DRF 10945 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 10945. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DRF 10945 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [366] | ||
E-3030 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for E-3030. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of E-3030 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [367] | ||
GSK-677954 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-677954. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK-677954 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [368] | ||
Indeglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Indeglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Indeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [7], [317] | ||
KRP-101 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KRP-101 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [369] | ||
KRP-105 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-105. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KRP-105 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [327] | ||
KRP-297 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-297. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KRP-297 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [356] | ||
LG-101280 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LG-101280. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LG-101280 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [370] | ||
LY-929 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-929. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY-929 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [371] | ||
MP-136 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MP-136. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MP-136 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [372] | ||
NS-220 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for NS-220. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NS-220 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [373] | ||
Reglixane [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Reglixane. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Reglixane through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [374] | ||
Sipoglitazar [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sipoglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Sipoglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [375] | ||
Sodelglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sodelglitazar. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Sodelglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [317], [376] | ||
Phosphogluconate dehydrogenase (PGD)
GHRP-2 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for GHRP-2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GHRP-2 through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [377], [378] | ||
(2R)-2-Methyl-4,5-dideoxy [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for (2R)-2-Methyl-4,5-dideoxy. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (2R)-2-Methyl-4,5-dideoxy through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [377], [379] | ||
4-phospho-D-erythronate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for 4-phospho-D-erythronate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-phospho-D-erythronate through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [377], [380] | ||
5-deoxy-5-phosphono-D-arabinonate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for 5-deoxy-5-phosphono-D-arabinonate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 5-deoxy-5-phosphono-D-arabinonate through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [90], [377] | ||
6-Phosphogluconic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for 6-Phosphogluconic Acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 6-Phosphogluconic Acid through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [377], [381] | ||
Pyrophosphate 2- [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Phosphogluconate dehydrogenase (PGD) is a therapeutic target for Pyrophosphate 2-. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pyrophosphate 2- through regulating the expression of Phosphogluconate dehydrogenase (PGD). | [89], [377] | ||
PI3-kinase beta (PIK3CB)
Buparlisib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for Buparlisib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase beta (PIK3CB). | [89], [382] | ||
PA-799 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PA-799. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [383] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PQR309. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PQR309 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [384] | ||
AZD8186 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for AZD8186. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD8186 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [385] | ||
BAY 1082439 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [386] | ||
GSK2636771 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for GSK2636771. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK2636771 through regulating the expression of PI3-kinase beta (PIK3CB). | [140], [382] | ||
3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [387] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [388] | ||
ISIS 31963 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31963. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 31963 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 31982 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31982. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 31982 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 31996 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 31996. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 31996 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32000. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32000 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32002. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32002 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32003. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32003 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32004 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32004. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32004 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32005 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32005. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32005 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32006 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32006. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32006 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32008 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32008. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32008 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32010 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32010. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32010 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32014 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32014. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32014 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32015 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32015. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32015 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32020. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32020 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32021 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32021. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32021 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32024. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32024 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32028 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32028. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32028 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32035 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32035. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32035 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [389] | ||
ISIS 32039 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for ISIS 32039. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 32039 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [390] | ||
KU-0060648 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for KU-0060648. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KU-0060648 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [391] | ||
LY-292223 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [390] | ||
PI-3065 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PI-3065. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PI-3065 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [388] | ||
PIK-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PIK-75. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PIK-75 through regulating the expression of PI3-kinase beta (PIK3CB). | [203], [382] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for PP121. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PP121 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [392] | ||
TGX-221 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase beta (PIK3CB) is a therapeutic target for TGX-221. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TGX-221 through regulating the expression of PI3-kinase beta (PIK3CB). | [382], [393] | ||
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). | [394], [395] | ||
Resten-NG [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). | [394], [396] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). | [34], [394] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [398] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [399] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [80], [397] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [400] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [171], [397] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [402] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [251], [397] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [74], [397] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [251], [397] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [251], [397] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [403] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [89], [397] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [404] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [405] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [251], [397] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [406] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [407] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [405] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [408] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [409] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [251], [397] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [410] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [397] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [409] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [397], [401] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [397] | ||
Serine sulfhydrase (CBS)
Arsenic [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine sulfhydrase (CBS) is a therapeutic target for Arsenic. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Arsenic through regulating the expression of Serine sulfhydrase (CBS). | [411], [412] | ||
OT-58 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine sulfhydrase (CBS) is a therapeutic target for OT-58. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OT-58 through regulating the expression of Serine sulfhydrase (CBS). | [171], [411] | ||
aminooxyacetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine sulfhydrase (CBS) is a therapeutic target for aminooxyacetic acid. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of aminooxyacetic acid through regulating the expression of Serine sulfhydrase (CBS). | [90], [411] | ||
Heme [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine sulfhydrase (CBS) is a therapeutic target for Heme. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Heme through regulating the expression of Serine sulfhydrase (CBS). | [411], [413] | ||
Serine/threonine-protein kinase mTOR (mTOR)
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Glasdegib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Glasdegib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [415] | ||
Novolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Novolimus. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Novolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [236], [414] | ||
Temsirolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Temsirolimus. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Temsirolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [416] | ||
Zotarolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Zotarolimus. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Zotarolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
Ridaforolimus [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ridaforolimus. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ridaforolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [418] | ||
ABI-009 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ABI-009. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABI-009 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [419] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD-2014. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD-2014 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
BEZ235 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BEZ235. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BEZ235 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [414] | ||
BGT226 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BGT226. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BGT226 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
CC-223 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CC-223. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CC-223 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [420] | ||
INK128 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [421] | ||
| Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [439] | |||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LY3023414. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY3023414 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [422] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ME-344. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ME-344 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [423] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for MM-141. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MM-141 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [414] | ||
OSI-027 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OSI-027. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OSI-027 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [424] | ||
PF-04691502 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-04691502. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-04691502 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [425] | ||
PF-05212384 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05212384. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-05212384 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [426] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PQR309. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PQR309 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [384], [414] | ||
Salirasib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Salirasib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Salirasib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
SAR245409 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SAR245409. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SAR245409 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [427] | ||
SF1126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SF1126. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SF1126 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [15], [414] | ||
BI 860585 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BI 860585. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BI 860585 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [428] | ||
DS-3078 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-3078. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DS-3078 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [429] | ||
DS-7423 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-7423. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DS-7423 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [430] | ||
GDC-0349 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for GDC-0349. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GDC-0349 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
LAM-001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LAM-001. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LAM-001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [431] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [171], [414] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for VS-5584. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VS-5584 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [432] | ||
(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [434] | ||
2-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
2-chloro-N-(6-cyanopyridin-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-chloro-N-(6-cyanopyridin-3-yl)propanamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-chloro-N-(6-cyanopyridin-3-yl)propanamide through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [435] | ||
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [436] | ||
3-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 3-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [437] | ||
4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
4-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 4-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
AP-21967 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AP-21967. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AP-21967 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [434] | ||
AR-mTOR-26 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AR-mTOR-26. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AR-mTOR-26 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
C-16-(S)-3-methylindolerapamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for C-16-(S)-3-methylindolerapamycin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of C-16-(S)-3-methylindolerapamycin through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [433] | ||
CU-906 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CU-906. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CU-906 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
EC-0565 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0565. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EC-0565 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
EC-0845 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0845. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EC-0845 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
EM-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EM-101. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of EM-101 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [438] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [436] | ||
HM-5016699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for HM-5016699. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of HM-5016699 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
OXA-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OXA-01. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OXA-01 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
P-2281 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-2281. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of P-2281 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
P-6915 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-6915. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of P-6915 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
PF-03772304 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-03772304. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-03772304 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
PF-05094037 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05094037. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-05094037 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [440] | ||
PP-242 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP-242. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PP-242 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [195], [414] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP121. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PP121 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [203], [414] | ||
Rapamycin complexed with immunophilin FKBP12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Rapamycin complexed with immunophilin FKBP12. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Rapamycin complexed with immunophilin FKBP12 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [436] | ||
SB-2280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SB-2280. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SB-2280 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
SX-MTR1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SX-MTR1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SX-MTR1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
torin 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for torin 1. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of torin 1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [203], [414] | ||
Torin2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Torin2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Torin2 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [441] | ||
X-387 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for X-387. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of X-387 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [417] | ||
AZD8055 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD8055. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZD8055 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [442] | ||
SCR-44001 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SCR-44001. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SCR-44001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [443] | ||
TAFA-93 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for TAFA-93. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TAFA-93 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [240], [414] | ||
Signal transducer and activator of transcription 1 (STAT1)
AVT-02 UE [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 1 (STAT1) is a therapeutic target for AVT-02 UE. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AVT-02 UE through regulating the expression of Signal transducer and activator of transcription 1 (STAT1). | [444], [445] | ||
Signal transducer and activator of transcription 3 (STAT3)
Acitretin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Acitretin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Acitretin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [445], [446] | ||
Napabucasin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Napabucasin. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Napabucasin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [447] | ||
Atiprimod [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Atiprimod. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Atiprimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [448] | ||
GLG-801 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GLG-801. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GLG-801 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [449] | ||
Golotimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Golotimod. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Golotimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [446] | ||
IMX-110 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for IMX-110. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of IMX-110 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [446] | ||
ISIS-STAT3 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS-STAT3. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS-STAT3 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
NT219 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for NT219. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NT219 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [451] | ||
OPB-31121 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-31121. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OPB-31121 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [446] | ||
WP-1066 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP-1066. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WP-1066 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [446] | ||
C188-9 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for C188-9. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of C188-9 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [452] | ||
DSP-0337 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for DSP-0337. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of DSP-0337 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [4], [446] | ||
OPB-111077 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-111077. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OPB-111077 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [453] | ||
OPB-51602 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-51602. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OPB-51602 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [454] | ||
TAK-114 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for TAK-114. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TAK-114 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [455] | ||
WP1220 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP1220. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of WP1220 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [456] | ||
GNF-PF-1399 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GNF-PF-1399. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GNF-PF-1399 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [457] | ||
ISIS 113176 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113176. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 113176 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
ISIS 113187 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113187. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 113187 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
ISIS 113209 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113209. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 113209 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
ISIS 113210 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113210. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 113210 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [446] | ||
ISIS 17148 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
ISIS 17152 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17152. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 17152 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [446], [450] | ||
Solute carrier family 45 member 4 (SLC45A4)
Sucrose [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Solute carrier family 45 member 4 (SLC45A4) is a therapeutic target for Sucrose. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Sucrose through regulating the expression of Solute carrier family 45 member 4 (SLC45A4). | [458], [459] | ||
Thrombospondin-1 (THBS1)
ABT-510 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). | [460], [461] | ||
CVX-045 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thrombospondin-1 (THBS1) is a therapeutic target for CVX-045. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CVX-045 through regulating the expression of Thrombospondin-1 (THBS1). | [460], [462] | ||
Transforming growth factor beta 1 (TGFB1)
Pirfenidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Pirfenidone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Pirfenidone through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [31], [280] | ||
LY2157299 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [280], [463] | ||
TG-C [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for TG-C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TG-C through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [269], [280] | ||
Disitertide [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Disitertide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Disitertide through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [15], [280] | ||
ABBV-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ABBV-151. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABBV-151 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [280], [464] | ||
SRK-181 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for SRK-181. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of SRK-181 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [280], [465] | ||
ART-144 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ART-144. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ART-144 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [280], [466] | ||
Mannose phosphate [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Mannose phosphate. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Mannose phosphate through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [280], [467] | ||
Tyrosine-protein kinase Mer (MERTK)
MK-2461 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for MK-2461. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MK-2461 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [468] | ||
ONO-7475 [Phase 1/2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for ONO-7475. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [254] | ||
| Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for ONO-7475. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [471] | |||
INCB81776 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for INCB81776. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of INCB81776 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [469] | ||
MRX-2843 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for MRX-2843. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MRX-2843 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [470] | ||
PF-07265807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for PF-07265807. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PF-07265807 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [472] | ||
RXDX-106 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for RXDX-106. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of RXDX-106 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [473] | ||
G749 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for G749. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of G749 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [474] | ||
LDC1267 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for LDC1267. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [475] | ||
UNC2025 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for UNC2025. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of UNC2025 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [15] | ||
UNC569 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for UNC569. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of UNC569 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). | [1], [476] | ||
ZNF217 messenger RNA (ZNF217 mRNA)
ISIS 114527 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114527. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114527 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114530 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114530. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114530 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114531 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114531. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114531 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114532 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114532. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114532 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114537 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114537. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114537 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114559 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114559. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114559 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
ISIS 114563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114563. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114563 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [479] | ||
ISIS 14548 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 14548. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 14548 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). | [477], [478] | ||
References